Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Innovotech Inc V.IOT

Innovotech Inc. is a Canadian biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.


TSXV:IOT - Post by User

Comment by colouramaon Sep 15, 2024 6:46pm
80 Views
Post# 36224753

RE:Announcement

RE:Announcement
Agree - I am intrigued since I wonder what implications this has with respect to the Innovosil-1 compound, and the majority stake in Nou Life. Just from a contract research perspective, they now have two labs; assuming this one is similar in size to Innovotech, that is a doubling of contract research revenue potentially? With the high margins (> 70%), this hopefully can fall to the bottom line nicely.

In the press release, they say "A further comprehensive press release will be issued upon the signing of a definitive agreement with respect to the Keystone acquisition", so look forward to more colour soon!
<< Previous
Bullboard Posts
Next >>